Publications

FDA turmoil reshapes biotech dealmaking terms

Quoted, Axios

Shareholder Chris Simpson discusses how ongoing uncertainty and instability at the FDA is reshaping the structure and negotiation of biotech and pharma deals.

(subscription required)